Vivos Therapeutics, Inc. (VVOS) — Financial statements
Income statement, balance sheet, and cash flow for Vivos Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 17↑16.0% | 15↑8.9% | 14↓13.9% | 16↓5.1% | 17 | |
| Cost of Revenue | 7↑14.8% | 6↑8.7% | 6↓7.9% | 6↑40.3% | 4 | |
| Gross Profit | 11↑16.9% | 9↑9.0% | 8↓17.4% | 10↓20.5% | 13 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 28↑55.1% | 18↓20.5% | 22↓22.6% | 29↑12.6% | 26 | |
| Selling & Marketing Expenses | 1↓19.1% | 2↓29.8% | 2↓53.8% | 5↓3.8% | 6 | |
| SG&A Expenses | 29↑48.5% | 20↓21.4% | 25↓27.4% | 34↑9.7% | 31 | |
| Other Expenses | 1↑125.3% | 0.58↓6.4% | 0.62↓7.2% | 0.67↓8.7% | 0.73 | |
| Operating Expenses | 30↑50.7% | 20↓21.0% | 26↓27.1% | 35↑9.3% | 32 | |
| Total Costs & Expenses | 37↑42.5% | 26↓15.7% | 31↓24.3% | 41↑12.9% | 36 | |
| Operating Results | ||||||
| Operating Income | -20↓78.1% | -11↑35.4% | -17↑30.9% | -25↓28.6% | -19 | |
| Depreciation & Amortization | 1↑125.3% | 0.58↓6.4% | 0.62↓7.2% | 0.67↓8.7% | 0.73 | |
| EBITDA | -19↓75.5% | -11↑36.5% | -17↑31.6% | -24↓24.7% | -20 | |
| EBIT | -20↓78.1% | -11↑35.4% | -17↑30.9% | -25↓23.5% | -20 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.09↓13.6% | 0.10 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.09↓23.9% | 0.12 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.80 | |
| Other Income / Expenses | -1↓3917.1% | 0.04↓99.1% | 4↑213.1% | 1↑245.2% | -0.82 | |
| Income Before Tax | -21↓90.6% | -11↑18.0% | -14↑43.0% | -24↓17.5% | -20 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -21↓90.6% | -11↑18.0% | -14↑43.0% | -24↓17.5% | -20 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -21↓90.6% | -11↑18.0% | -14↑43.0% | -24↓17.5% | -20 | |
| Bottom-Line Net Income | -21↓90.6% | -11↑18.0% | -14↑43.0% | -24↓17.5% | -20 | |
| EPS (Basic) | -2.06↑7.2% | -2.22↑80.1% | -11.14↑57.0% | -25.90↓8.4% | -23.89 | |
| EPS (Diluted) | -2.06↑7.2% | -2.22↑80.1% | -11.14↑57.0% | -25.90↓8.4% | -23.89 | |
| Weighted Average Shares | 10↑104.7% | 5↑311.7% | 1↑32.5% | 0.92↑8.4% | 0.85 | |
| Weighted Average Diluted Shares | 10↑104.7% | 5↑311.7% | 1↑32.5% | 0.92↑8.4% | 0.85 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.